Inventor · disambiguated record
Holly Kordasiewicz
Also filed as: KORDASIEWICZ HOLLY
20 granted patents·13 pending applications·73 citations·filing 2010–2024
94Inventor score
Top patents by PatentIndex Score
33 records- 0195US10407680B2Compounds and methods for reducing Tau expressionIONIS PHARMACEUTICALS INC·Filed 2017·Granted Sep 10, 2019·12 cites·31 claims
- 0295US9273315B2Modulation of huntingtin expressionISIS PHARMACEUTICALS INC·Filed 2014·Granted Mar 1, 2016·19 cites·14 claims
- 0393US10837016B2Modulation of huntingtin expressionIONIS PHARMACEUTICALS INC·Filed 2020·Granted Nov 17, 2020·2 cites·16 claims
- 0492US10793856B2Compositions for modulating Tau expressionBIOGEN MA INC·Filed 2017·Granted Oct 6, 2020·9 cites·58 claims
- 0591US11591595B2Compositions for modulating Tau expressionBIOGEN MA INC·Filed 2020·Granted Feb 28, 2023·2 cites·34 claims
- 0690US10619158B2Modulation of huntingtin expressionIONIS PHARMACEUTICALS INC·Filed 2019·Granted Apr 14, 2020·2 cites·16 claims
- 0789US11959080B2Methods and compositions for inhibiting PMP22 expressionIONIS PHARMACEUTICALS INC·Filed 2021·Granted Apr 16, 2024·1 cites·29 claims
- 0889US11136577B2Methods and compositions for inhibiting PMP22 expressionIONIS PHARMACEUTICALS INC·Filed 2017·Granted Oct 5, 2021·4 cites·25 claims
- 0989US9683236B2Modulation of huntingtin expressionIONIS PHARMACEUTICALS INC·Filed 2016·Granted Jun 20, 2017·5 cites·16 claims
- 1087US11421231B2Modulation of Huntington expressionIONIS PHARMACEUTICALS INC·Filed 2020·Granted Aug 23, 2022·1 cites·16 claims
- 1186US10907160B2Methods for reducing LRRK2 expressionIONIS PHARMACEUTICALS INC·Filed 2017·Granted Feb 2, 2021·4 cites·48 claims
- 1285US12091662B2Compositions for modulating tau expressionBIOGEN MA INC·Filed 2023·Granted Sep 17, 2024·0 cites·15 claims
- 1385US8906873B2Modulation of huntingtin expressionHUNG GENE·Filed 2010·Granted Dec 9, 2014·8 cites·8 claims
- 1484US10202603B2Modulation of huntingtin expressionIONIS PHARMACEUTICALS INC·Filed 2017·Granted Feb 12, 2019·2 cites·16 claims
- 1583US11053498B2Compounds and methods for reducing Tau expressionBIOGEN MA INC·Filed 2019·Granted Jul 6, 2021·1 cites·38 claims
- 1683US2024301422A1Compounds and methods for reducing tau expressionBIOGEN MA INC·Filed 2024·Application pending·0 cites
- 1782US12297431B2Modulation of huntingtin expressionIONIS PHARMACEUTICALS INC·Filed 2022·Granted May 13, 2025·0 cites·14 claims
- 1880US2024401039A1Compounds and Methods for Reducing ATXN2 ExpressionIONIS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1978US11230712B2Compounds and methods for reducing SNCA expressionIONIS PHARMACEUTICALS INC·Filed 2018·Granted Jan 25, 2022·1 cites·25 claims
- 2077US12350285B2Compounds and methods for reducing ATXN3 expressionIONIS PHARMACEUTICALS INC·Filed 2023·Granted Jul 8, 2025·0 cites·21 claims
- 2165US2025051781A1Compounds and methods for modulating glycogen synthase 1IONIS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2265US2022315923A1Compounds and methods for reducing snca expressionIONIS PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2363US11530411B2Methods for reducing LRRK2 expressionIONIS PHARMACEUTICALS INC·Filed 2020·Granted Dec 20, 2022·0 cites·25 claims
- 2463US2025320493A1Methods for reducing tau expressionBIOGEN MA INC·Filed 2022·Application pending·0 cites
- 2562US2025346907A1Compounds and methods for reducing glycogen synthase 1IONIS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2662US2024376469A1Compounds and methods for modulating huntingtinIONIS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2758US11492615B2Antisense compounds and uses thereofIONIS PHARMACEUTICALS INC·Filed 2018·Granted Nov 8, 2022·0 cites·15 claims
- 2857US2023374519A1Compounds and methods for modulating pmp22IONIS PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2956US2023357770A1Compounds and methods for reducing apoe expressionIONIS PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3055US2022380773A1Compounds and methods for reducing app expressionIONIS PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3152US2016138014A1Antisense compounds and uses thereofISIS PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 3248US2022195431A1Compounds and methods for reducing atxn3 expressionIONIS PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3344US2019211332A1Compounds and methods for reducing tau expressionIONIS PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Holly Kordasiewicz files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →